Hydrogenology
Source-linked study record

Hydrogen inhalation improves mouse neurological outcomes after cerebral ischemia/reperfusion independent of anti-necroptosis

Huang JL, Liu WW, Sun XJ. · Medical Gas Research. 2018;8(1):1–5.

PreclinicalInhaled H₂Published 2018Source checked
Study record, not medical adviceThis record reports what the source states. It is not medical advice and does not establish that molecular hydrogen is effective, safe or appropriate for any person.
Quick summary

Study at a glance

Evidence type

Preclinical

Population or model

C57BL mice with one hour of middle-cerebral-artery occlusion followed by reperfusion.

Intervention and dose

Beginning at reperfusion, mice inhaled the test gas for 90 minutes. · 66.7% H₂ and 33.3% O₂ from an AMS-H-01 hydrogen/oxygen nebulizer.

Duration

Ninety minutes from the start of reperfusion; most outcomes at 24 hours, with MLKL time points through 72 hours.

Reported result

Infarct ratio was 20.21±4.43% with oxyhydrogen versus 39.51±5.30% with untreated ischemia-reperfusion and 34.83±3.53% with N₂/O₂ control. Brain water and neurological scores also favored oxyhydrogen. MLKL protein and mRNA were not changed by the intervention, so the proposed anti-necroptosis mechanism was not supported.

Main limitation

Preclinical short-term stroke model, assay-specific small groups, no consolidated animal total, no reported total gas flow, no functional follow-up beyond the acute period and mechanistic tests that were null. Chinese National Natural Science Foundation grants funded the work; authors declared no conflict of interest.

Evidence and classification

What kind of evidence is this?

Evidence type

Preclinical

Reported design

Randomized controlled mouse middle-cerebral-artery occlusion experiment

Research topic

Other neurological conditions

Administration form

Inhaled H₂

Information not yet classified

Some editorial classification fields are still pending. The source-reported outcomes and result are shown below; Hydrogenology does not infer a positive or negative signal from prose automatically.

Reported in the source

Methods

Population or model

C57BL mice with one hour of middle-cerebral-artery occlusion followed by reperfusion.

Sample

Assay-specific group sizes were n=8 for infarct ratio, n=5 for brain water, n=17–18 for neurological score and n=3–5 for molecular assays; the article does not provide one consolidated animal total.

Duration

Ninety minutes from the start of reperfusion; most outcomes at 24 hours, with MLKL time points through 72 hours.

Intervention

Beginning at reperfusion, mice inhaled the test gas for 90 minutes.

Hydrogen form

Brown's gas / oxyhydrogen — H₂ and O₂ co-generated by water electrolysis.

Dose or H₂ specification

66.7% H₂ and 33.3% O₂ from an AMS-H-01 hydrogen/oxygen nebulizer.

H₂ flow

Not reported — gas composition is given but total generator flow is absent, so H₂ mL/min cannot be calculated.

O₂ delivered with H₂

33.3% O₂ was co-delivered; O₂ flow in mL/min was not reported.

Comparator

A 66.7% N₂/33.3% O₂ gas control, plus untreated ischemia-reperfusion and sham groups.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Infarct ratio, brain water content, neurological deficit and MLKL protein/mRNA expression as a necroptosis-pathway measure.

Reported result

Infarct ratio was 20.21±4.43% with oxyhydrogen versus 39.51±5.30% with untreated ischemia-reperfusion and 34.83±3.53% with N₂/O₂ control. Brain water and neurological scores also favored oxyhydrogen. MLKL protein and mRNA were not changed by the intervention, so the proposed anti-necroptosis mechanism was not supported.

Extraction completeness

The complete free article, oxyhydrogen composition, assay-specific sample sizes, positive and null results, stated limitations, funding and conflict declaration were checked.

A reported association, difference or mechanism is not automatically a clinical benefit.

Interpretation limits

Limitations and applicability

Main methodological cautions

Preclinical short-term stroke model, assay-specific small groups, no consolidated animal total, no reported total gas flow, no functional follow-up beyond the acute period and mechanistic tests that were null. Chinese National Natural Science Foundation grants funded the work; authors declared no conflict of interest.

Applies directly to

Acute focal cerebral ischemia-reperfusion in mice; not evidence of treatment efficacy in people with stroke.

No single-study GRADE certainty rating is assigned. Read how records and evidence assessments are prepared.

Sources and status

Sources and record status

Identifiers

PMID: 29770189 · DOI: 10.4103/2045-9912.229596

Publisher access

Open-access PubMed Central article.

Extraction basis

Complete PubMed Central article and PubMed metadata; full-text extraction checked 9 August 2026.

Last reviewed

10 August 2026

Help the next reader

Help people check the facts before they buy.

Hydrogenology keeps 665 source-checked records accessible without advertising or product promotion.

Support independent access
Help us correct the recordReport a discrepancy

Send the exact difference between this page and the linked source. The study reference is attached automatically.